Description of Tirzepatide intermediates and clinical trials

For energy metabolism FDA approved phase 3 are once-weekly dual GIP and GLP receptors that are persistently effective as side chains, such as Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH (CAS:2460751- 66-8), C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH, C20-Glu-AEEA-AEEA-OSU, and C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH (CAS1188328-37- 1). Next, I will give you a description of Tirzepatide intermediates and clinical trials. Here are some answers.

Here is the content list:

l Product description for Tirzepatide intermediates.

l About SURPASS-4 and the SURPASS clinical trial program.

Product description for Tirzepatide intermediates.

Tirzepatide intermediates are generally pale yellow or white or white powder in appearance and it is used in pharmaceutical intermediates. Our chemical synthesized powder lab high purity solution is packaged in glass bottles inside and paper drums outside. Our company can ship our Tirzepatide intermediates to any port in China and we accept production orders of 1kg or more. Our Tirzepatide intermediates have a purity of greater than or equal to 98% and isomers of less than or equal to 0.1%. We recommend that Tirzepatide intermediates are stored below 20°C, preferably at 2-8°C. We ship by CIF air or DAP courier, FOB, EXW, etc.

About SURPASS-4 and the SURPASS clinical trial program.

SURPASS-4 (NCT03730662) is a randomized, parallel, open-label trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg, and 15 mg with glargine insulin in adults with type 2 diabetes who have at least one and up to three oral anti-hyperglycaemic drugs (metformin, sulphonylurea or SGLT) that increase cardiovascular (CV) risk. sulfonylureas or SGLT-2 inhibitors). The trial randomized 2,002 study participants in a 1:1:1:3 ratio to receive either 5mg, 10mg, or 15mg of biology long acting phase 2 or glargine insulin. Participants were from the EU, North America (Canada and USA), Australia, Israel, Taiwan, and Latin America (Brazil, Argentina, and Mexico). The primary objective of the study was to demonstrate that Tirzepatide intermediates (10 mg and/or 15 mg) were not inferior to glargine insulin in patients with type 2 diabetes and increased cardiovascular risk in terms of change from baseline A1C at week 52. The primary and key secondary endpoints were measured at week 52 and participants continued treatment for up to 104 weeks or until study completion. Completion of the study was triggered by the occurrence of a major adverse cardiovascular event (MACE). Participants enrolled in the study must have a mean baseline A1C between 7.5% and 10.5% and a BMI at baseline greater than or equal to 25 kg/m2. All participants in the tripeptide intermediates treatment group started the study at a dose of tripeptide 2. 5 mg once weekly, followed by gradual dose increases at 4-week intervals to a final randomized maintenance dose of 5 mg (via the 2.5 mg step), 10 mg (via the 2.5 mg, 5 mg, and 7.5 mg steps) or 15 mg (via the 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 12.5 mg steps). All participants in the titrated glargine insulin treatment group started with a baseline dose of 10 units per day and were titrated according to a treatment target algorithm to achieve fasting glucose below 100 mg/dL. Tirzepatide intermediates' SURPASS Phase 3 global clinical development program has enrolled more than 20,000 people with type 2 diabetes in 10 clinical trials, five of which are global registry studies. The program commenced in late 2018 and has now completed all five global registration trials.

Our official website is https://www.pu-kang.com/. If you work with Tirzepatide intermediates or would like to learn more about our company, you can talk to us on the website. Our cost-effective products are very popular with everyone. We will be happy to provide more and better services with high-quality Tirzepatide intermediates products, good services, and competitive prices!